## Matthew E Falagas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5222179/publications.pdf

Version: 2024-02-01

423 papers

33,953 citations

94 h-index 167 g-index

426 all docs

426 docs citations

times ranked

426

30757 citing authors

#	Article	IF	CITATIONS
1	Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses. FASEB Journal, 2008, 22, 338-342.	0.5	2,671
2	Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial Infections. Clinical Infectious Diseases, 2005, 40, 1333-1341.	5.8	1,396
3	Â-D-Glucan Assay for the Diagnosis of Invasive Fungal Infections: A Meta-analysis. Clinical Infectious Diseases, 2011, 52, 750-770.	5.8	997
4	Pandrug Resistance (PDR), Extensive Drug Resistance (XDR), and Multidrug Resistance (MDR) among Gramâ€Negative Bacilli: Need for International Harmonization in Terminology. Clinical Infectious Diseases, 2008, 46, 1121-1122.	5.8	769
5	Obesity and infection. Lancet Infectious Diseases, The, 2006, 6, 438-446.	9.1	701
6	Adjunctive therapies for community-acquired pneumonia: a systematic review. Journal of Antimicrobial Chemotherapy, 2008, 62, 661-668.	3.0	606
7	Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Critical Care, 2006, 10, R27.	5.8	604
8	Deaths Attributable to Carbapenem-Resistant <i>Enterobacteriaceae</i> Infections. Emerging Infectious Diseases, 2014, 20, 1170-1175.	4.3	432
9	Fosfomycin. Clinical Microbiology Reviews, 2016, 29, 321-347.	13.6	426
10	Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum $\hat{I}^2$ -lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infectious Diseases, The, 2010, 10, 43-50.	9.1	425
10	producing, Enterobacteriaceae infections: a systematic review. Lancet Infectious Diseases, The, 2010, 10,	9.1	425 396
	producing, Enterobacteriaceae infections: a systematic review. Lancet Infectious Diseases, The, 2010, 10, 43-50.  Comparison of SCImago journal rank indicator with journal impact factor. FASEB Journal, 2008, 22,		
11	producing, Enterobacteriaceae infections: a systematic review. Lancet Infectious Diseases, The, 2010, 10, 43-50.  Comparison of SCImago journal rank indicator with journal impact factor. FASEB Journal, 2008, 22, 2623-2628.  Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet	0.5	396
11 12	producing, Enterobacteriaceae infections: a systematic review. Lancet Infectious Diseases, The, 2010, 10, 43-50.  Comparison of SCImago journal rank indicator with journal impact factor. FASEB Journal, 2008, 22, 2623-2628.  Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infectious Diseases, The, 2008, 8, 751-762.  Risk factors for cardiac implantable electronic device infection: a systematic review and	9.1	396 378
11 12 13	producing, Enterobacteriaceae infections: a systematic review. Lancet Infectious Diseases, The, 2010, 10, 43-50.  Comparison of SCImago journal rank indicator with journal impact factor. FASEB Journal, 2008, 22, 2623-2628.  Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infectious Diseases, The, 2008, 8, 751-762.  Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. Europace, 2015, 17, 767-777.  Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?. International Journal	0.5 9.1 1.7	396 378 355
11 12 13	producing, Enterobacteriaceae infections: a systematic review. Lancet Infectious Diseases, The, 2010, 10, 43-50.  Comparison of SCImago journal rank indicator with journal impact factor. FASEB Journal, 2008, 22, 2623-2628.  Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infectious Diseases, The, 2008, 8, 751-762.  Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. Europace, 2015, 17, 767-777.  Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?. International Journal of Antimicrobial Agents, 2007, 29, 630-636.  Informed consent: how much and what do patients understand?. American Journal of Surgery, 2009,	0.5 9.1 1.7 2.5	396 378 355 331
11 12 13 14	producing, Enterobacteriaceae infections: a systematic review. Lancet Infectious Diseases, The, 2010, 10, 43-50.  Comparison of SCImago journal rank indicator with journal impact factor. FASEB Journal, 2008, 22, 2623-2628.  Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infectious Diseases, The, 2008, 8, 751-762.  Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. Europace, 2015, 17, 767-777.  Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?. International Journal of Antimicrobial Agents, 2007, 29, 630-636.  Informed consent: how much and what do patients understand?. American Journal of Surgery, 2009, 198, 420-435.  The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter	0.5 9.1 1.7 2.5	396 378 355 331

#	Article	IF	CITATIONS
19	Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. International Journal of Infectious Diseases, 2010, 14, e954-e966.	3.3	284
20	Fosfomycin: Use Beyond Urinary Tract and Gastrointestinal Infections. Clinical Infectious Diseases, 2008, 46, 1069-1077.	5.8	266
21	Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. International Journal of Antimicrobial Agents, 2010, 35, 194-199.	2.5	261
22	Sex differences in the incidence and severity of respiratory tract infections. Respiratory Medicine, 2007, 101, 1845-1863.	2.9	257
23	Clinical Outcomes With Extended or Continuous Versus Short-term Intravenous Infusion of Carbapenems and Piperacillin/Tazobactam: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2013, 56, 272-282.	5.8	247
24	Resistance to polymyxins: Mechanisms, frequency and treatment options. Drug Resistance Updates, 2010, 13, 132-138.	14.4	238
25	Prolonged versus short-term intravenous infusion of antipseudomonal $\hat{l}^2$ -lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infectious Diseases, The, 2018, 18, 108-120.	9.1	235
26	Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: A meta-analysis of randomized controlled trials*. Critical Care Medicine, 2010, 38, 954-962.	0.9	234
27	Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. International Journal of Antimicrobial Agents, 2012, 40, 1-8.	2.5	218
28	Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Critical Care, 2006, 10, R48.	5.8	213
29	Effect of Aminoglycoside and βâ€Lactam Combination Therapy versus βâ€Lactam Monotherapy on the Emergence of Antimicrobial Resistance: A Metaâ€analysis of Randomized, Controlled Trials. Clinical Infectious Diseases, 2005, 41, 149-158.	5.8	210
30	Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. Journal of Antimicrobial Chemotherapy, 2007, 60, 1124-1130.	3.0	209
31	Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infectious Diseases, The, 2005, 5, 581-589.	9.1	202
32	Potential of old-generation antibiotics to address current need for new antibiotics. Expert Review of Anti-Infective Therapy, 2008, 6, 593-600.	4.4	201
33	Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. Journal of Antimicrobial Chemotherapy, 2006, 58, 266-272.	3.0	198
34	Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. Journal of Antimicrobial Chemotherapy, 2012, 67, 255-268.	3.0	189
35	Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. Journal of Antimicrobial Chemotherapy, 2007, 60, 214-236.	3.0	187
36	The top-ten in journal impact factor manipulation. Archivum Immunologiae Et Therapiae Experimentalis, 2008, 56, 223-226.	2.3	186

#	Article	IF	CITATIONS
37	Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infectious Diseases, 2005, 5, 24.	2.9	177
38	Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Critical Care, 2005, 9, R53.	5.8	175
39	Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. Journal of Antimicrobial Chemotherapy, 2008, 62, 45-55.	3.0	170
40	Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clinical Rheumatology, 2007, 26, 663-670.	2.2	167
41	Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: A prospective study. Respiratory Medicine, 2008, 102, 407-412.	2.9	167
42	Serum procalcitonin as a diagnostic marker for neonatal sepsis: a systematic review and meta-analysis. Intensive Care Medicine, 2011, 37, 747-762.	8.2	167
43	Do we still need the aminoglycosides?. International Journal of Antimicrobial Agents, 2009, 33, 201-205.	2.5	165
44	Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. Journal of Antimicrobial Chemotherapy, 2008, 62, 889-894.	3.0	163
45	Candida Albicans Versus Non-Albicans Intensive Care Unit-Acquired Bloodstream Infections: Differences in Risk Factors and Outcome. Anesthesia and Analgesia, 2008, 106, 523-529.	2.2	163
46	Combination Therapy with Intravenous Colistin for Management of Infections Due to Multidrug-Resistant Gram-Negative Bacteria in Patients without Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2005, 49, 3136-3146.	3.2	160
47	Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. International Journal of Antimicrobial Agents, 2009, 34, 111-120.	2.5	159
48	Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. International Journal of Antimicrobial Agents, 2009, 34, 506-515.	2.5	159
49	Factors associated with suboptimal compliance to vaccinations in children in developed countries: a systematic review. Current Medical Research and Opinion, 2008, 24, 1719-1741.	1.9	156
50	Do Psychological Variables Affect Early Surgical Recovery?. PLoS ONE, 2011, 6, e20306.	2.5	155
51	Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Critical Care, 2007, 11, 134.	5.8	153
52	Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. Journal of Antimicrobial Chemotherapy, 2008, 62, 895-904.	3.0	153
53	Attributable mortality of <i>Stenotrophomonas maltophilia </i> livinfections: a systematic review of the literature. Future Microbiology, 2009, 4, 1103-1109.	2.0	152
54	Statins for infection and sepsis: a systematic review of the clinical evidence. Journal of Antimicrobial Chemotherapy, 2008, 61, 774-785.	3.0	150

#	Article	IF	CITATIONS
55	Linezolid versus glycopeptide or β-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infectious Diseases, The, 2008, 8, 53-66.	9.1	149
56	Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. BMJ: British Medical Journal, 1998, 316, 110-116.	2.3	148
57	Risk Factors for Mortality in Patients With Emphysematous Pyelonephritis: A Meta-Analysis. Journal of Urology, 2007, 178, 880-885.	0.4	148
58	Risk factors associated with the isolation of colistin-resistant Gram-negative bacteria: A matched case-control study. Critical Care Medicine, 2008, 36, 807-811.	0.9	148
59	The effect of psychosocial factors on breast cancer outcome: a systematic review. Breast Cancer Research, 2007, 9, R44.	5.0	147
60	Treatment of <i>Acinetobacter </i> iiinfections. Expert Opinion on Pharmacotherapy, 2010, 11, 779-788.	1.8	146
61	Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. Journal of Antimicrobial Chemotherapy, 2006, 58, 273-280.	3.0	145
62	Substandard/Counterfeit Antimicrobial Drugs. Clinical Microbiology Reviews, 2015, 28, 443-464.	13.6	145
63	Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infectious Diseases, 2005, 5, 1.	2.9	144
64	MRSA in Africa: Filling the Global Map of Antimicrobial Resistance. PLoS ONE, 2013, 8, e68024.	2.5	144
65	Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. International Journal of Antimicrobial Agents, 2010, 35, 240-243.	2.5	143
66	Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Review of Anti-Infective Therapy, 2007, 5, 811-821.	4.4	142
67	Therapeutic options for infections with <i>Enterobacteriaceae</i> producing carbapenem-hydrolyzing enzymes. Future Microbiology, 2011, 6, 653-666.	2.0	141
68	Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: The study, the patient, the bug or the drug?. Journal of Infection, 2013, 66, 401-414.	3.3	140
69	Probiotics for the treatment of allergic rhinitis and asthma: systematic review of randomized controlled trials. Annals of Allergy, Asthma and Immunology, 2008, 101, 570-579.	1.0	137
70	Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. International Journal of Antimicrobial Agents, 2007, 29, 9-25.	2.5	136
71	Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: Characteristics and outcome in a series of 28 patients. International Journal of Antimicrobial Agents, 2008, 32, 450-454.	2.5	135
72	Nephrotoxicity of intravenous colistin: a prospective evaluation. International Journal of Antimicrobial Agents, 2005, 26, 504-507.	2.5	134

#	Article	IF	CITATIONS
73	Short- versus Long-Course Antibacterial Therapy for Community-Acquired Pneumonia. Drugs, 2008, 68, 1841-1854.	10.9	132
74	Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet, The, 2010, 375, 248-251.	13.7	127
75	Probiotics for Prevention of Recurrent Urinary Tract Infections in Women. Drugs, 2006, 66, 1253-1261.	10.9	125
76	Impact of patient position on the incidence of ventilator-associated pneumonia: A meta-analysis of randomized controlled trials. Journal of Critical Care, 2009, 24, 515-522.	2.2	125
77	The Use of Intravenous and Aerosolized Polymyxins for the Treatment of Infections in Critically III Patients: A Review of the Recent Literature. Clinical Medicine and Research, 2006, 4, 138-146.	0.8	124
78	The role of aminoglycosides in combination with a $\hat{l}^2$ -lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. Journal of Antimicrobial Chemotherapy, 2006, 57, 639-647.	3.0	124
79	Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. British Journal of Haematology, 2005, 131, 22-28.	2.5	121
80	The Impact of Article Length on the Number of Future Citations: A Bibliometric Analysis of General Medicine Journals. PLoS ONE, 2013, 8, e49476.	2.5	121
81	Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy, 2010, 65, 1862-1877.	3.0	120
82	Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. International Journal of Antimicrobial Agents, 2016, 48, 1-10.	2.5	120
83	A Bibliometric Analysis of Global Research Production in Respiratory Medicine. Chest, 2005, 128, 3993-3998.	0.8	118
84	Risk Factors for Meshâ€related Infections After Hernia Repair Surgery: A Metaâ€analysis of Cohort Studies. World Journal of Surgery, 2011, 35, 2389-2398.	1.6	115
85	Resistance to fosfomycin: Mechanisms, Frequency and Clinical Consequences. International Journal of Antimicrobial Agents, 2019, 53, 22-28.	2.5	114
86	Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Annals of Intensive Care, 2011, 1, 30.	4.6	110
87	Stenotrophomonas maltophilia Infections in a General Hospital: Patient Characteristics, Antimicrobial Susceptibility, and Treatment Outcome. PLoS ONE, 2012, 7, e37375.	2.5	108
88	Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: A meta-analysis of randomized, placebo-controlled trials*. Critical Care Medicine, 2006, 34, 1216-1224.	0.9	107
89	Rifampicin-impregnated central venous catheters: a meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy, 2007, 59, 359-369.	3.0	105
90	Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature. International Journal of Antimicrobial Agents, 2016, 47, 269-285.	2.5	104

#	Article	IF	Citations
91	$\hat{l}^2$ -Lactam plus aminoglycoside or fluoroquinolone combination versus $\hat{l}^2$ -lactam monotherapy for Pseudomonas aeruginosa infections: A meta-analysis. International Journal of Antimicrobial Agents, 2013, 41, 301-310.	2.5	102
92	Probiotics for the Treatment or Prevention of Atopic Dermatitis. American Journal of Clinical Dermatology, 2008, 9, 93-103.	6.7	99
93	Colistin and Polymyxin B in Critical Care. Critical Care Clinics, 2008, 24, 377-391.	2.6	98
94	Antibiotics versus placebo in the treatment of women with uncomplicated cystitis: A meta-analysis of randomized controlled trials. Journal of Infection, 2009, 58, 91-102.	3.3	98
95	Linezolid for the Treatment of Patients with Central Nervous System Infection. Annals of Pharmacotherapy, 2007, 41, 296-308.	1.9	97
96	Laser therapy for the genitourinary syndrome of menopause. A systematic review and meta-analysis. Maturitas, 2017, 103, 78-88.	2.4	96
97	Impact of passive humidification on clinical outcomes of mechanically ventilated patients: A meta-analysis of randomized controlled trials *. Critical Care Medicine, 2007, 35, 2843-2851.	0.9	95
98	A bibliometric analysis of global trends of research productivity in tropical medicine. Acta Tropica, 2006, 99, 155-159.	2.0	94
99	Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. Journal of Antimicrobial Chemotherapy, 2006, 57, 1251-1254.	3.0	94
100	Socioeconomic status (SES) as a determinant of adherence to treatment in HIV infected patients: a systematic review of the literature. Retrovirology, 2008, 5, 13.	2.0	94
101	Comparison of antibiotics with placebo for treatment of acute sinusitis: a meta-analysis of randomised controlled trials. Lancet Infectious Diseases, The, 2008, 8, 543-552.	9.1	94
102	Pharmacological Considerations for the Proper Clinical Use of Aminoglycosides. Drugs, 2011, 71, 2277-2294.	10.9	94
103	Probiotics for the prevention of respiratory tract infections: a systematic review. International Journal of Antimicrobial Agents, 2009, 34, 197.e1-197.e10.	2.5	91
104	Antimicrobial-impregnated and -coated shunt catheters for prevention of infections in patients with hydrocephalus: a systematic review and meta-analysis. Journal of Neurosurgery, 2015, 122, 1096-1112.	1.6	91
105	Susceptibility of Urinary Tract Bacteria to Fosfomycin. Antimicrobial Agents and Chemotherapy, 2009, 53, 4508-4510.	3.2	90
106	Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opinion on Investigational Drugs, 2009, 18, 921-944.	4.1	90
107	Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: a meta-analysis of comparative trials. Critical Care, 2006, 10, R123.	5.8	89
108	Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. Journal of Antimicrobial Chemotherapy, 2017, 72, 1704-1708.	3.0	89

#	Article	IF	Citations
109	Arrhythmias associated with fluoroquinolone therapy. International Journal of Antimicrobial Agents, 2007, 29, 374-379.	2.5	88
110	Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis. Journal of Antimicrobial Chemotherapy, 2007, 60, 1216-1226.	3.0	87
111	Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a systematic review of the clinical evidence. International Journal of Antimicrobial Agents, 2009, 33, 394-404.	2.5	87
112	Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. Lancet Infectious Diseases, The, 2005, 5, 431-439.	9.1	86
113	Infectious complications of monoclonal antibodies used in cancer therapy. Cancer, 2007, 109, 2182-2189.	4.1	86
114	The safety of polymyxin antibiotics. Expert Opinion on Drug Safety, 2015, 14, 1687-1701.	2.4	85
115	Hyaluronic Acid: An Effective Alternative Treatment of Interstitial Cystitis, Recurrent Urinary Tract Infections, and Hemorrhagic Cystitis?. European Urology, 2007, 51, 1534-1541.	1.9	84
116	PREDICTORS OF MORTALITY IN ADULT PATIENTS WITH VENTILATOR-ASSOCIATED PNEUMONIA. Shock, 2010, 33, 590-601.	2.1	84
117	Frequency, characteristics, and predictors of microbiologically documented nosocomial infections after cardiac surgery. European Journal of Cardio-thoracic Surgery, 2006, 29, 456-460.	1.4	83
118	Outcomes after medical and surgical treatment of diverticulitis: A systematic review of the available evidence. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 1360-1368.	2.8	83
119	Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis. International Journal of Antimicrobial Agents, 2017, 49, 233-238.	2.5	83
120	Ampicillin/Sulbactam. Drugs, 2007, 67, 1829-1849.	10.9	82
121	Linezolid for the treatment of adults with bone and joint infections. International Journal of Antimicrobial Agents, 2007, 29, 233-239.	2.5	82
122	Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence. Expert Review of Anti-Infective Therapy, 2013, 11, 321-331.	4.4	82
123	Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. Journal of Thoracic Disease, 2015, 7, 603-15.	1.4	81
124	From conference abstract to full paper: differences between data presented in conferences and journals. FASEB Journal, 2005, 19, 673-680.	0.5	80
125	Current diagnosis and management of infectious mononucleosis. Current Opinion in Hematology, 2012, 19, 14-20.	2.5	80
126	Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. International Journal of Antimicrobial Agents, 2014, 44, 1-7.	2.5	80

#	Article	IF	CITATIONS
127	Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria. European Journal of Clinical Pharmacology, 2010, 66, 359-368.	1.9	79
128	Use of International Units When Dosing Colistin Will Help Decrease Confusion Related to Various Formulations of the Drug around the World. Antimicrobial Agents and Chemotherapy, 2006, 50, 2274-2275.	3.2	78
129	Does the use of probiotics/synbiotics prevent postoperative infections in patients undergoing abdominal surgery? A meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology, 2009, 65, 561-570.	1.9	77
130	Comparison of amount of biomedical research originating from the European Union and the United States. BMJ: British Medical Journal, 2005, 331, 192-194.	2.3	75
131	A bibliometric analysis of research productivity in Parasitology by different world regions during a 9-year period (1995–2003). BMC Infectious Diseases, 2006, 6, 56.	2.9	75
132	Mesh-related infections after pelvic organ prolapse repair surgery. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2007, 134, 147-156.	1.1	75
133	Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. Cmaj, 2008, 179, 1269-1277.	2.0	75
134	Early Switch to Oral Treatment in Patients with Moderate to Severe Community-Acquired Pneumonia. Drugs, 2008, 68, 2469-2481.	10.9	70
135	Frequency, prevention, outcome and treatment of ventilator-associated tracheobronchitis: Systematic review and meta-analysis. Respiratory Medicine, 2010, 104, 325-336.	2.9	69
136	Estimates of global production in cardiovascular diseases research. International Journal of Cardiology, 2005, 100, 443-449.	1.7	68
137	Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence. International Journal of Antimicrobial Agents, 2007, 30, 202-209.	2.5	68
138	Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: a meta-analysis. International Journal of Infectious Diseases, 2012, 16, e768-e773.	3.3	67
139	Impact of passive humidification on clinical outcomes of mechanically ventilated patients: A meta-analysis of randomized controlled trials*. Critical Care Medicine, 2007, 35, 2843-2851.	0.9	66
140	Aminoglycoside therapy in infectious diseases. Expert Opinion on Pharmacotherapy, 2013, 14, 1585-1597.	1.8	65
141	Arab science in the golden age (750–1258 C.E.) and today. FASEB Journal, 2006, 20, 1581-1586.	0.5	64
142	Oral rifampin for eradication of Staphylococcus aureus carriage fromÂhealthy and sick populations: AÂsystematic review of the evidence from comparative trials. American Journal of Infection Control, 2007, 35, 106-114.	2.3	64
143	Options for treating carbapenem-resistant Enterobacteriaceae. Current Opinion in Infectious Diseases, 2014, 27, 479-483.	3.1	64
144	Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis. International Journal of Antimicrobial Agents, 2018, 51, 1-9.	2.5	64

#	Article	IF	Citations
145	Attributable Mortality of Acinetobacter baumannii Infection among Critically III Patients. Clinical Infectious Diseases, 2006, 43, 389-389.	5.8	63
146	Interstitial Cystitis. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1844-1857.	4.5	63
147	Characteristics, risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit. Journal of Infection, 2015, 70, 592-599.	3.3	63
148	Old antibiotics for infections in critically ill patients. Current Opinion in Critical Care, 2007, 13, 592-597.	3.2	62
149	The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?. Expert Review of Anti-Infective Therapy, 2016, 14, 747-763.	4.4	62
150	A bibliometric analysis by geographic area of published research in several biomedical fields, 1995-2003. Cmaj, 2006, 175, 1389-1390.	2.0	61
151	CO 2 -laser for the genitourinary syndrome of menopause. How many laser sessions?. Maturitas, 2017, 104, 24-28.	2.4	61
152	Aspects of the association between leishmaniasis and malignant disorders. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2007, 101, 1181-1189.	1.8	60
153	Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials. International Journal of Antimicrobial Agents, 2007, 30, 213-221.	2.5	59
154	Impact of Antibiotic MIC on Infection Outcome in Patients with Susceptible Gram-Negative Bacteria: a Systematic Review and Meta-Analysis. Antimicrobial Agents and Chemotherapy, 2012, 56, 4214-4222.	3.2	59
155	Ciprofloxacin vs an Aminoglycoside in Combination With a $\hat{l}^2$ -Lactam for the Treatment of Febrile Neutropenia: A Meta-analysis of Randomized Controlled Trials. Mayo Clinic Proceedings, 2005, 80, 1146-1156.	3.0	57
156	Continuous versus Intermittent Intravenous Administration of Antibacterials with Time-Dependent Action. Drugs, 2005, 65, 2499-2511.	10.9	57
157	Polymyxins: old antibiotics are back. Lancet, The, 2006, 367, 633-634.	13.7	57
158	Comparison of First-Line With Second-Line Antibiotics for Acute Exacerbations of Chronic Bronchitis. Chest, 2007, 132, 447-455.	0.8	57
159	Atelectasis as a Cause of Postoperative Fever. Chest, 2011, 140, 418-424.	0.8	57
160	Maternal Influenza Vaccination and Risk for Congenital Malformations. Obstetrics and Gynecology, 2015, 126, 1075-1084.	2.4	57
161	Imiquimod for the treatment of actinic keratosis: A meta-analysis of randomized controlled trials. Journal of the American Academy of Dermatology, 2006, 55, 537-538.	1.2	56
162	Re-emergence of colistin in today's world of multidrug-resistant organisms: personal perspectives. Expert Opinion on Investigational Drugs, 2008, 17, 973-981.	4.1	56

#	Article	IF	Citations
163	Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. Journal of Antimicrobial Chemotherapy, 2008, 62, 442-450.	3.0	56
164	Effectiveness and safety of short <i>&gt;vs</i> >. long duration of antibiotic therapy for acute bacterial sinusitis: a metaâ€analysis of randomized trials. British Journal of Clinical Pharmacology, 2009, 67, 161-171.	2.4	56
165	Cure of post-traumatic recurrent multiresistant Gram-negative rod meningitis with intraventricular colistin. Journal of Infection, 2005, 50, 348-352.	3.3	55
166	Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. Journal of Antimicrobial Chemotherapy, 2007, 60, 7-19.	3.0	55
167	Nephrotoxicity of Colistin: New Insight into an Old Antibiotic. Clinical Infectious Diseases, 2009, 48, 1729-1731.	5.8	55
168	Intravenous Colistimethate (Colistin) Use in Critically III Children Without Cystic Fibrosis. Pediatric Infectious Disease Journal, 2009, 28, 123-127.	2.0	55
169	Age Distribution of Cases of 2009 (H1N1) Pandemic Influenza in Comparison with Seasonal Influenza. PLoS ONE, 2011, 6, e21690.	2.5	55
170	Worldwide trends in quantity and quality of published articles in the field of infectious diseases. BMC Infectious Diseases, 2005, $5$ , $16$ .	2.9	54
171	Research contribution of different world regions in the top 50 biomedical journals (1995–2002). FASEB Journal, 2006, 20, 29-34.	0.5	53
172	Treatment options for 2009 H1N1 influenza: evaluation of the published evidence. International Journal of Antimicrobial Agents, 2010, 35, 421-430.	2.5	53
173	An update on adverse drug reactions related to $\hat{I}^2$ -lactam antibiotics. Expert Opinion on Drug Safety, 2018, 17, 499-508.	2.4	52
174	Mapping Health Literacy Research in the European Union: A Bibliometric Analysis. PLoS ONE, 2008, 3, e2519.	2.5	52
175	Inhaled colistin as monotherapy for multidrug-resistant gram (â^') nosocomial pneumonia: A case series. Respiratory Medicine, 2009, 103, 707-713.	2.9	51
176	Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis. International Journal of Antimicrobial Agents, 2018, 51, 535-547.	2.5	51
177	Efficacy and Safety of Telavancin in Clinical Trials: A Systematic Review and Meta-Analysis. PLoS ONE, 2012, 7, e41870.	2.5	51
178	Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy, 2010, 65, 1330-1346.	3.0	50
179	Tetracyclines for multidrug-resistant Acinetobacter baumannii infections. International Journal of Antimicrobial Agents, 2015, 45, 455-460.	2.5	50
180	Imiquimod for treatment of vulvar and vaginal intraepithelial neoplasia. International Journal of Gynecology and Obstetrics, 2008, 101, 3-10.	2.3	49

#	Article	IF	CITATIONS
181	Albendazole versus Praziquantel in the Treatment of Neurocysticercosis: A Meta-analysis of Comparative Trials. PLoS Neglected Tropical Diseases, 2008, 2, e194.	3.0	49
182	Clinical Significance of the Pharmacokinetic and Pharmacodynamic Characteristics of Tigecycline. Current Drug Metabolism, 2009, 10, 13-21.	1.2	49
183	Comparison of utility of blood cultures from intravascular catheters and peripheral veins: a systematic review and decision analysis. Journal of Medical Microbiology, 2008, 57, 1-8.	1.8	49
184	Clinical Features, Risk Factors, and Complications Among Pediatric Patients With Pandemic Influenza A (H1N1). Clinical Pediatrics, 2010, 49, 777-781.	0.8	47
185	Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin. Scandinavian Journal of Infectious Diseases, 2005, 37, 142-145.	1.5	46
186	Intravenous heparin in combination with antibiotics for the treatment of deep vein septic thrombophlebitis: A systematic review. European Journal of Pharmacology, 2007, 557, 93-98.	3.5	46
187	Short- versus long-course antibiotic therapy for acute pyelonephritis in adolescents and adults: A meta-analysis of randomized controlled trials. Clinical Therapeutics, 2008, 30, 1859-1868.	2.5	46
188	Effect of meteorological variables on the incidence of respiratory tract infections. Respiratory Medicine, 2008, 102, 733-737.	2.9	45
189	Epidemiologic, clinical characteristics, and risk factors for adverse outcome in multiresistant gram-negative primary bacteremia of critically ill patients. American Journal of Infection Control, 2011, 39, 396-400.	2.3	45
190	Trimethoprim/sulfamethoxazole for Acinetobacter spp.: A review of current microbiological and clinical evidence. International Journal of Antimicrobial Agents, 2015, 46, 231-241.	2.5	45
191	Tuberculosis in patients with systemic rheumatic or pulmonary diseases treated with glucocorticosteroids and the preventive role of isoniazid: a review of the available evidence. International Journal of Antimicrobial Agents, 2007, 30, 477-486.	2.5	44
192	Antibiotics versus placebo or watchful waiting for acute otitis media: a meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy, 2009, 64, 16-24.	3.0	44
193	A systematic review of trends in the methodological quality of randomized controlled trials in various research fields. Journal of Clinical Epidemiology, 2009, 62, 227-231.e9.	5.0	44
194	Systemic colistin use in children without cystic fibrosis: a systematic review of the literature. International Journal of Antimicrobial Agents, 2009, 33, 503.e1-503.e13.	2.5	44
195	Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: A meta-analysis of randomized controlled trials. American Heart Journal, 2007, 154, 144-150.	2.7	43
196	Impact of vancomycin minimum inhibitory concentration on clinical outcomes of patients with vancomycin-susceptible Staphylococcus aureus infections: a meta-analysis and meta-regression. International Journal of Antimicrobial Agents, 2012, 40, 496-509.	2.5	43
197	Bacterial interference for the prevention and treatment of infections. International Journal of Antimicrobial Agents, 2008, 31, 518-522.	2.5	41
198	Fluoroquinolones compared with Â-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials. Cmaj, 2008, 178, 845-854.	2.0	41

#	Article	IF	Citations
199	A prospective study of characteristics and outcomes of bacteremia in patients with solid organ or hematologic malignancies. Supportive Care in Cancer, 2013, 21, 2521-2526.	2.2	41
200	Benefit-Risk Assessment of Linezolid for Serious Gram-Positive Bacterial Infections. Drug Safety, 2008, 31, 753-768.	3.2	40
201	Efficacy of vaginal therapies alternative to vaginal estrogens on sexual function and orgasm of menopausal women: A systematic review and meta-analysis of randomized controlled trials. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 229, 45-56.	1.1	40
202	Gentamicin collagen sponges for the prevention of sternal wound infection: A meta-analysis of randomized controlled trials. Journal of Thoracic and Cardiovascular Surgery, 2012, 144, 1235-1240.	0.8	39
203	Hepatitis B vaccine alone or with hepatitis B immunoglobulin in neonates of HBsAg+/HBeAgâ^' mothers: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2015, 70, 396-404.	3.0	39
204	Reaction to the threat of influenza pandemic: the mass media and the public. Critical Care, 2006, 10, 408.	5.8	38
205	FREQUENCY AND PREDICTORS OF VENTILATOR-ASSOCIATED PNEUMONIA RECURRENCE. Shock, 2008, 30, 487-495.	2.1	38
206	Infections Related to Coils Used for Embolization of Arteries: Review of the Published Evidence. Journal of Vascular and Interventional Radiology, 2007, 18, 697-701.	0.5	37
207	Outcome of Antimicrobial Therapy in Documented Biofilm-Associated Infections. Drugs, 2009, 69, 1351-1361.	10.9	37
208	Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin. International Journal of Antimicrobial Agents, 2010, 35, 497-499.	2.5	37
209	Patients included in randomised controlled trials do not represent those seen in clinical practice: focus on antimicrobial agents. International Journal of Antimicrobial Agents, 2010, 36, 1-13.	2.5	37
210	Urinary Tract Infections in Patients With Urinary Diversion. American Journal of Kidney Diseases, 2005, 46, 1030-1037.	1.9	36
211	Surfing The Web: World Wide Web Resources on Antimicrobial Resistance. Clinical Infectious Diseases, 2006, 43, 630-633.	5.8	35
212	"Eigenlob― selfâ€citation in biomedical journals. FASEB Journal, 2006, 20, 1039-1042.	0.5	35
213	Percutaneous Exposure Incidents of the Health Care Personnel in a Newly Founded Tertiary Hospital: A Prospective Study. PLoS ONE, 2007, 2, e194.	2.5	35
214	Effectiveness and Safety of Short-Course vs Long-Course Antibiotic Therapy for Group A $\hat{l}^2$ -Hemolytic Streptococcal Tonsillopharyngitis: A Meta-analysis of Randomized Trials. Mayo Clinic Proceedings, 2008, 83, 880-889.	3.0	35
215	Safety of Hepatitis B, Pneumococcal Polysaccharide and Meningococcal Polysaccharide Vaccines in Pregnancy. Drug Safety, 2012, 35, 1-14.	3.2	35
216	Seasonality of mortality: the September phenomenon in Mediterranean countries. Cmaj, 2009, 181, 484-486.	2.0	34

#	Article	IF	Citations
217	Evaluation of fosfomycin activity against uropathogens in a fosfomycin-naive population in South India: a prospective study. Future Microbiology, 2013, 8, 675-680.	2.0	34
218	Worldwide research productivity in critical care medicine. Critical Care, 2005, 9, R258.	5.8	33
219	Fluoroquinolones vs $\hat{l}^2$ -Lactams for Empirical Treatment of Immunocompetent Patients With Skin and Soft Tissue Infections: A Meta-analysis of Randomized Controlled Trials. Mayo Clinic Proceedings, 2006, 81, 1553-1566.	3.0	33
220	Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer. Expert Opinion on Pharmacotherapy, 2007, 8, 1743-1755.	1.8	33
221	Exposure to quinolones is associated with carbapenem resistance among colistin-susceptible Acinetobacter baumannii blood isolates. International Journal of Antimicrobial Agents, 2007, 30, 409-414.	2.5	33
222	The risk of using the Internet as reference resource: A comparative study. International Journal of Medical Informatics, 2008, 77, 280-286.	3.3	33
223	Compliance with Once-Daily versus Twice or Thrice-Daily Administration of Antibiotic Regimens: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2015, 10, e0116207.	2.5	33
224	Linezolid: effectiveness and safety for approved and off-label indications. Expert Opinion on Pharmacotherapy, 2007, 8, 2381-2400.	1.8	32
225	Antimicrobial susceptibility of Gram-negative nonurinary bacteria to fosfomycin and other antimicrobials. Future Microbiology, 2010, 5, 961-970.	2.0	32
226	Impact of Vacuum-Assisted Closure (VAC) Therapy on Clinical Outcomes of Patients with Sternal Wound Infections: A Meta-Analysis of Non-Randomized Studies. PLoS ONE, 2013, 8, e64741.	2.5	32
227	Impact of Definitive Therapy with Beta-Lactam Monotherapy or Combination with an Aminoglycoside or a Quinolone for Pseudomonas aeruginosa Bacteremia. PLoS ONE, 2011, 6, e26470.	2.5	32
228	Effectiveness and Safety of Tigecycline: Focus on Use for Approved Indications. Clinical Infectious Diseases, 2012, 54, 1672-1674.	5.8	31
229	Once versus multiple daily dosing of aminoglycosides for patients with febrile neutropenia: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2011, 66, 251-259.	3.0	30
230	Pyomyositis associated with hematological malignancy: case report and review of the literature. International Journal of Infectious Diseases, 2008, 12, 120-125.	3.3	29
231	Antimicrobial Prophylaxis in Surgery: An International Survey. Surgical Infections, 2010, 11, 343-348.	1.4	29
232	Meta-analysis of Randomized Controlled Trials of Vancomycin for the Treatment of Patients With Gram-Positive Infections: Focus on the Study Design. Mayo Clinic Proceedings, 2012, 87, 349-363.	3.0	29
233	Impact of Initial Discordant Treatment With $\hat{l}^2$ -Lactam Antibiotics on Clinical Outcomes in Adults With Pneumococcal Pneumonia: A Systematic Review. Mayo Clinic Proceedings, 2006, 81, 1567-1574.	3.0	28
234	Microbiologically documented nosocomial infections after coronary artery bypass surgery without cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery, 2006, 132, 481-490.	0.8	28

#	Article	IF	CITATIONS
235	Aspergillus fumigatus tricuspid native valve endocarditis in a non-intravenous drug user. Journal of Medical Microbiology, 2006, 55, 635-638.	1.8	28
236	Prolonged survival of an HIV-infected patient with plasmablastic lymphoma of the oral cavity. American Journal of Hematology, 2007, 82, 761-765.	4.1	28
237	A Comparative Study on the Cost of New Antibiotics and Drugs of Other Therapeutic Categories. PLoS ONE, 2006, 1, e11.	2.5	28
238	Caspofungin for the treatment of fungal infections: a systematic review of randomized controlled trials. International Journal of Antimicrobial Agents, 2007, 29, 136-143.	2.5	27
239	Do PubMed and Google searches help medical students and young doctors reach the correct diagnosis? A pilot study. European Journal of Internal Medicine, 2009, 20, 788-790.	2.2	27
240	New antibiotics: optimal use in current clinical practice. International Journal of Antimicrobial Agents, 2009, 34, S55-S62.	2.5	27
241	Meta-analyses on Behavioral Interventions to Reduce the Risk of Transmission of HIV. Infectious Disease Clinics of North America, 2009, 23, 309-314.	5.1	27
242	An analysis of factors contributing to PubMed's growth. Journal of Informetrics, 2015, 9, 592-617.	2.9	27
243	Urinary tract infections after pelvic floor gynecological surgery: prevalence and effect of antimicrobial prophylaxis. A systematic review. International Urogynecology Journal, 2008, 19, 1165-1172.	1.4	26
244	New antibiotic agents for bloodstream infections. International Journal of Antimicrobial Agents, 2008, 32, S60-S65.	2.5	26
245	Evaluation of Antimicrobial Susceptibility of Enterobacteriaceae Causing Urinary Tract Infections in Africa. Antimicrobial Agents and Chemotherapy, 2013, 57, 3628-3639.	3.2	26
246	In vitro activity of fosfomycin in combination with linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus. Journal of Antibiotics, 2014, 67, 369-371.	2.0	26
247	Intravenous plus inhaled versus intravenous colistin monotherapy for lower respiratory tract infections: A systematic review and meta-analysis. Journal of Infection, 2018, 76, 321-327.	3.3	26
248	Clinical use of intravenous polymyxin B for the treatment of patients with multidrug-resistant Gram-negative bacterial infections: An evaluation of the current evidence. Journal of Global Antimicrobial Resistance, 2021, 24, 342-359.	2.2	26
249	Trends in the Impact Factor of Scientific Journals. Mayo Clinic Proceedings, 2006, 81, 1401-1402.	3.0	25
250	Clinical decision-making based on findings presented in conference abstracts: is it safe for our patients?. European Heart Journal, 2006, 27, 2038-2039.	2.2	25
251	Use of ACE inhibitors and risk of community-acquired pneumonia: a review. European Journal of Clinical Pharmacology, 2008, 64, 565-573.	1.9	25
252	Candida albicans versus non-albicans bloodstream infection in patients in a tertiary hospital: An analysis of microbiological data. Scandinavian Journal of Infectious Diseases, 2008, 40, 414-419.	1.5	25

#	Article	IF	CITATIONS
253	Update on the safety of linezolid. Expert Opinion on Drug Safety, 2009, 8, 485-491.	2.4	25
254	Extended or continuous versus short-term intravenous infusion of cephalosporins: a meta-analysis. Expert Review of Anti-Infective Therapy, 2013, 11, 585-595.	4.4	25
255	Tigecycline for the treatment of patients with Clostridium difficile infection: an update of the clinical evidence. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1053-1058.	2.9	25
256	Estimates of global research productivity in virology. Journal of Medical Virology, 2005, 76, 229-223.	5.0	24
257	At what age do biomedical scientists do their best work?. FASEB Journal, 2008, 22, 4067-4070.	0.5	24
258	Knowledge and practices regarding prevention of infections associated with central venous catheters: A survey of intensive care unit medical and nursing staff. American Journal of Infection Control, 2011, 39, 542-547.	2.3	23
259	Secular trends of antimicrobial resistance of blood isolates in a newly founded Greek hospital. BMC Infectious Diseases, 2006, 6, 99.	2.9	22
260	Oral rifampin for prevention of S. aureus carriage-related infections in patients with renal failureâ€"a meta-analysis of randomized controlled trials. Nephrology Dialysis Transplantation, 2006, 21, 2536-2542.	0.7	21
261	WHEN TO INCLUDE POLYMYXINS IN THE EMPIRICAL ANTIBIOTIC REGIMEN IN CRITICALLY ILL PATIENTS WITH FEVER? A DECISION ANALYSIS APPROACH. Shock, 2007, 27, 605-609.	2.1	21
262	Continuous versus Conventional Infusion of Amphotericin B Deoxycholate: A Meta-Analysis. PLoS ONE, 2013, 8, e77075.	2.5	21
263	Inhaled antibiotics beyond aminoglycosides, polymyxins and aztreonam: A systematic review. International Journal of Antimicrobial Agents, 2015, 45, 221-233.	2.5	21
264	Clinical relevance of in vitro synergistic activity of antibiotics for multidrug-resistant Gram-negative infections: A systematic review. Journal of Global Antimicrobial Resistance, 2019, 17, 250-259.	2.2	21
265	Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options. Current Opinion in Investigational Drugs, 2008, 9, 176-83.	2.3	21
266	Patients' Perception of Quality of Pre-Operative Informed Consent in Athens, Greece: A Pilot Study. PLoS ONE, 2009, 4, e8073.	2.5	20
267	In Vitro Susceptibility to Various Antibiotics of Colistinâ€Resistant Gramâ€Negative Bacterial Isolates in a General Tertiary Hospital in Crete, Greece. Clinical Infectious Diseases, 2010, 50, 1689-1691.	5.8	20
268	H1N1v influenza vaccine in Greek medical students. European Journal of Public Health, 2011, 21, 329-332.	0.3	20
269	Ventilator-associated sinusitis in adults: Systematic review and meta-analysis. Respiratory Medicine, 2012, 106, 1082-1095.	2.9	20
270	Frequency of the off-label use of antibiotics in clinical practice: a systematic review. Expert Review of Anti-Infective Therapy, 2012, 10, 1383-1392.	4.4	20

#	Article	IF	CITATIONS
271	Streptococcus agalactiae infections in non-pregnant adults: single center experience of a growing clinical problem. Medical Science Monitor, 2006, 12, CR447-51.	1.1	20
272	Administration of antibiotics via the respiratory tract as monotherapy for pneumonia. Expert Review of Anti-Infective Therapy, 2008, 6, 447-452.	4.4	19
273	Effectiveness and Safety of Short-Course vs Long-Course Antibiotic Therapy for Group A $\hat{I}^2$ -Hemolytic Streptococcal Tonsillopharyngitis: A Meta-analysis of Randomized Trials. Mayo Clinic Proceedings, 2008, 83, 880-889.	3.0	19
274	Inhaled colistin for the treatment of tracheobronchitis and pneumonia in critically ill children without cystic fibrosis. Pediatric Pulmonology, 2010, 45, 1135-1140.	2.0	19
275	Ciprofloxacin/metronidazole versus $\hat{I}^2$ -lactam-based treatment of intra-abdominal infections: a meta-analysis of comparative trials. International Journal of Antimicrobial Agents, 2006, 28, 159-165.	2.5	18
276	World Wide Web resources on control of nosocomial infections. Critical Care, 2007, 11, 101.	5.8	18
277	Meta-analyses on the Optimization of the Duration of Antimicrobial Treatment for Various Infections. Infectious Disease Clinics of North America, 2009, 23, 269-276.	5.1	18
278	<i>In Vitro</i> Antimicrobial Susceptibility to Isepamicin of 6,296 Enterobacteriaceae Clinical Isolates Collected at a Tertiary Care University Hospital in Greece. Antimicrobial Agents and Chemotherapy, 2012, 56, 3067-3073.	3.2	18
279	Colistin loading dose: evaluation of the published pharmacokinetic and clinical data. International Journal of Antimicrobial Agents, 2016, 48, 475-484.	2.5	18
280	Antimicrobial resistance of Esherichia coli urinary isolates from primary care patients in Greece. Medical Science Monitor, 2008, 14, CR75-79.	1.1	18
281	The significance of different formulations of aerosolized colistin. Critical Care, 2005, 9, 417.	5.8	17
282	Risk Factors for Isolation of Strains Susceptible Only to Polymyxin among Patients with Pseudomonas aeruginosa Bacteremia. Antimicrobial Agents and Chemotherapy, 2006, 50, 2541-2543.	3.2	17
283	Science in Greece: from the age of Hippocrates to the age of the genome. FASEB Journal, 2006, 20, 1946-1950.	0.5	17
284	Synergistic activity of colistin with azidothymidine against colistin-resistant Klebsiella pneumoniae clinical isolates collected from inpatients in Greek hospitals. International Journal of Antimicrobial Agents, 2019, 53, 855-858.	2.5	17
285	Nosocomial infections after off-pump coronary artery bypass surgery: frequency, characteristics, and risk factors. Interactive Cardiovascular and Thoracic Surgery, 2007, 6, 759-767.	1.1	16
286	Antistaphylococcal penicillins versus cephalosporins for definitive treatment of meticillin-susceptible Staphylococcus aureus bacteraemia: A systematic review and meta-analysis. International Journal of Antimicrobial Agents, 2014, 44, 486-492.	2.5	16
287	Current Treatment of Pseudomonal Infections in the Elderly. Drugs and Aging, 2009, 26, 363-379.	2.7	15
288	The Role of Infection in Carotid Plaque Pathogenesis and Stability: The Clinical Evidence. Current Vascular Pharmacology, 2010, 8, 861-872.	1.7	15

#	Article	IF	CITATIONS
289	Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections. International Journal of Antimicrobial Agents, 2011, 37, 283-290.	2.5	15
290	Determination of MIC Distribution of Arbekacin, Cefminox, Fosfomycin, Biapenem and Other Antibiotics against Gram-Negative Clinical Isolates in South India: A Prospective Study. PLoS ONE, 2014, 9, e103253.	2.5	15
291	Developments on antibiotics for multidrug resistant bacterial Gram-negative infections. Expert Review of Anti-Infective Therapy, 2019, 17, 387-401.	4.4	15
292	Oral decontamination with chlorhexidine reduces the incidence of nosocomial pneumonia. Critical Care, 2006, 11, 402.	5 <b>.</b> 8	14
293	An analysis of patient house calls in the area of Attica, Greece. BMC Health Services Research, 2006, 6, 112.	2.2	14
294	Intravenous fosfomycin for the treatment of patients with central nervous system infections: evaluation of the published evidence. Expert Review of Anti-Infective Therapy, 2020, 18, 657-668.	4.4	14
295	Spotlight on Early COVID-19 Research Productivity: A 1-Year Bibliometric Analysis. Frontiers in Public Health, 2022, 10, .	2.7	14
296	Multidrug-resistant tuberculous spondylodiscitis: need for aggressive management and drug susceptibility testing of Mycobacterium tuberculosis isolates. Journal of Infection, 2006, 52, e35-e37.	3.3	13
297	Case report: Parotid abscess due to Salmonella enterica serovar Enteritidis in an immunocompetent adult. International Journal of Medical Microbiology, 2007, 297, 123-126.	3.6	13
298	Resiniferatoxin in the treatment of interstitial cystitis: a systematic review. International Urogynecology Journal, 2008, 19, 1571-1576.	1.4	13
299	Decreasing the incidence and impact of infections in neutropenic patients: evidence from meta-analyses of randomized controlled trials. Current Medical Research and Opinion, 2008, 24, 215-235.	1.9	13
300	Article and Journal Impact Factor in Various Scientific Fields. American Journal of the Medical Sciences, 2008, 335, 188-191.	1.1	13
301	Meta-analyses on Pediatric Infections and Vaccines. Infectious Disease Clinics of North America, 2009, 23, 431-457.	5.1	13
302	Inadequate Statistical Power of Published Comparative Cohort Studies on Ventilatorâ€Associated Pneumonia to Detect Mortality Differences. Clinical Infectious Diseases, 2010, 50, 468-472.	5.8	13
303	The pleiotropic effects of statins and omega-3 fatty acids against sepsis: a new perspective. Expert Opinion on Investigational Drugs, 2010, 19, 809-814.	4.1	13
304	Susceptibility of Gram-negative bacteria to isepamicin: a systematic review. Expert Review of Anti-Infective Therapy, 2012, 10, 207-218.	4.4	13
305	Ertapenem use and antimicrobial resistance to group 2 carbapenems in Gram-negative infections: a systematic review. Expert Review of Anti-Infective Therapy, 2013, 11, 69-78.	4.4	13
306	Susceptibility patterns of uropathogens identified in hospitalised children with community-acquired urinary tract infections in Thrace, Greece. Journal of Global Antimicrobial Resistance, 2015, 3, 85-90.	2.2	13

#	Article	IF	CITATIONS
307	Intravenous fosfomycin for the treatment of patients with bone and joint infections: a review. Expert Review of Anti-Infective Therapy, 2022, 20, 33-43.	4.4	13
308	Effectiveness and safety of short-course vs long-course antibiotic therapy for group a beta hemolytic streptococcal tonsillopharyngitis: a meta-analysis of randomized trials. Mayo Clinic Proceedings, 2008, 83, 880-9.	3.0	13
309	Frequency and predictors of colonization of the respiratory tract by VIM-2-producing Pseudomonas aeruginosa in patients of a newly established intensive care unit. Journal of Medical Microbiology, 2006, 55, 1435-1439.	1.8	12
310	Early switch to oral versus intravenous antimicrobial treatment for hospitalized patients with acute pyelonephritis: a systematic review of randomized controlled trials. Current Medical Research and Opinion, 2008, 24, 3423-3434.	1.9	12
311	Tigecycline for the treatment of patients with community-acquired pneumonia requiring hospitalization. Expert Review of Anti-Infective Therapy, 2009, 7, 913-923.	4.4	12
312	Biomedical research productivity in Greece: effect of the financial crisis. International Journal of Epidemiology, 2012, 41, 1206-1207.	1.9	12
313	Epidemiology and Antimicrobial Sensitivities of 536 Multi-Drug-Resistant Gram-Negative Bacilli Isolated from Patients Treated on Surgical Wards. Surgical Infections, 2012, 13, 326-331.	1.4	12
314	Tigecycline for carbapenem-resistant Klebsiellapneumoniaeinfections in the intensive care unit. Infectious Diseases, 2015, 47, 751-753.	2.8	12
315	Temporal Trends in the Impact Factor of European versus USA Biomedical Journals. PLoS ONE, 2011, 6, e16300.	2.5	12
316	Penicillins vs trimethoprim-based regimens for acute bacterial exacerbations of chronic bronchitis: meta-analysis of randomized controlled trials. Canadian Family Physician, 2009, 55, 60-7.	0.4	12
317	Cure of persistent, post-appendectomy Klebsiella pneumoniae septicaemia with continuous intravenous administration of meropenem. Scandinavian Journal of Infectious Diseases, 2006, 38, 807-810.	1.5	11
318	Infectious Disease Cases for Educational Purposes: Open-Access Resources on the Internet. Clinical Infectious Diseases, 2007, 45, 495-500.	5.8	11
319	Bowel Cleansing Before Bowel Surgery: Major Discordance Between Evidence and Practice. Journal of Gastrointestinal Surgery, 2008, 12, 919-920.	1.7	11
320	Optimal duration of the antimicrobial treatment of ventilator-acquired pneumonia. Expert Review of Anti-Infective Therapy, 2008, 6, 861-866.	4.4	11
321	Enhanced and earlier detection of bacteremia and fungemia by multiplex polymerase chain reaction: How much enhanced, how much earlier, and at what cost?*. Critical Care Medicine, 2008, 36, 1660-1661.	0.9	11
322	Increasing dominance of English in publications archived by PubMed. Scientometrics, 2009, 81, 219-223.	3.0	11
323	Case–Control Studies Reporting on Risk Factors for Emergence of Antimicrobial Resistance: Bias Associated with the Selection of the Control Group. Microbial Drug Resistance, 2010, 16, 303-308.	2.0	11
324	World Wide Web hepatitis B virus resources. Journal of Clinical Virology, 2007, 38, 161-164.	3.1	10

#	Article	IF	Citations
325	"But many that are first shall be last; and the last shall be first― FASEB Journal, 2009, 23, 1283-1284.	0.5	10
326	Systematic Reviews and Meta-analyses in Infectious Diseases: How are They Done and What are Their Strengths and Limitations?. Infectious Disease Clinics of North America, 2009, 23, 181-194.	5.1	10
327	Pulmonary drug delivery systems for antimicrobial agents: facts and myths. International Journal of Antimicrobial Agents, 2010, 35, 101-106.	2.5	10
328	Immediate hematological toxicity of linezolid in healthy volunteers with different body weight: a phase I clinical trial. Journal of Antibiotics, 2012, 65, 175-178.	2.0	10
329	Weight-adjusted versus fixed dose of linezolid for Chinese healthy volunteers of higher and lower body weight: a Phase I pharmacokinetic and pharmacodynamic study. Expert Opinion on Investigational Drugs, 2013, 22, 309-315.	4.1	10
330	<i>In vitro</i> susceptibility and resistance phenotypes in contemporary <i>Citrobacter</i> isolates in a University Hospital in Crete, Greece. Infectious Diseases, 2017, 49, 532-539.	2.8	10
331	Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals. International Journal of Antimicrobial Agents, 2018, 52, 269-271.	2.5	10
332	Unique Author Identification Number in Scientific Databases: A Suggestion. PLoS Medicine, 2006, 3, e249.	8.4	9
333	Prevalence and predictors of tuberculin skin positivity in Hellenic Army recruits. BMC Infectious Diseases, 2006, 6, 102.	2.9	9
334	Do high doses of quinolones decrease the emergence of antibacterial resistance? A systematic review of data from comparative clinical trials. Journal of Infection, 2007, 55, 97-105.	3.3	9
335	Benefits of Aerosolized Colistin for Ventilator-Associated Pneumonia: Absence of Proof Versus Proof of Absence?. Clinical Infectious Diseases, 2011, 52, 1278-1279.	5.8	9
336	Urinary tract analgesics for the treatment of patients with acute cystitis: where is the clinical evidence?. Expert Review of Anti-Infective Therapy, 2012, 10, 875-879.	4.4	9
337	Spotlight on inhaled ciprofloxacin and its potential in the treatment of non-cystic fibrosis bronchiectasis. Drug Design, Development and Therapy, 2018, Volume 12, 4059-4066.	4.3	9
338	Fluoroquinolone-based versus $\hat{l}^2$ -lactam-based regimens for complicated intra-abdominal infections: a meta-analysis of randomised controlled trials. International Journal of Antimicrobial Agents, 2019, 53, 746-754.	2.5	9
339	Penetration of the English language in science: the case of a German national interdisciplinary critical care conference. Critical Care, 2005, 9, 655.	5.8	8
340	Free Internal Medicine Case-Based Education Through the World Wide Web: How, Where, and With What?. Mayo Clinic Proceedings, 2007, 82, 203-207.	3.0	8
341	Aspects of Informed Consent in Medical Practice in the Eastern Mediterranean Region During the 17th and 18th Centuries. World Journal of Surgery, 2007, 31, 1587-1591.	1.6	8
342	Trends in the methodological quality of published randomized controlled trials on antibacterial agents. British Journal of Clinical Pharmacology, 2008, 65, 942-954.	2.4	8

#	Article	IF	Citations
343	Meta-analysis on Surgical Infections. Infectious Disease Clinics of North America, 2009, 23, 405-430.	5.1	8
344	Evaluation of a direct test for seasonal influenza in outpatients. European Journal of Internal Medicine, 2010, 21, 434-438.	2.2	8
345	Trimethoprim/sulfametrole: evaluation of the available clinical and pharmacokinetic/pharmacodynamic evidence. International Journal of Antimicrobial Agents, 2011, 38, 197-216.	2.5	8
346	Frequency of the off-label use of monoclonal antibodies in clinical practice: a systematic review of the literature. Current Medical Research and Opinion, 2014, 30, 471-480.	1.9	8
347	The dilemma of monotherapy or combination therapy in communityâ€acquired pneumonia. European Journal of Clinical Investigation, 2017, 47, e12845.	3.4	8
348	Polymyxins A Word of Caution for Prudent Use of Valuable "Old Antibiotics― Infection Control and Hospital Epidemiology, 2006, 27, 995-995.	1.8	7
349	Scalp necrosis: a rare complication of temporal arteritis. Clinical Rheumatology, 2007, 26, 1169-1169.	2.2	7
350	Do Changes in Antimicrobial Resistance Necessitate Reconsideration of Surgical Antimicrobial Prophylaxis Strategies?. Surgical Infections, 2009, 10, 557-562.	1.4	7
351	Linezolid for patients with neutropenia: are bacteriostatic agents appropriate?. Expert Review of Anti-Infective Therapy, 2009, 7, 415-422.	4.4	7
352	Biological mesh for abdominal wall hernia synthetic mesh multidrug-resistant Pseudomonas aeruginosa infection: Report of a case. Surgery Today, 2011, 41, 717-720.	1.5	7
353	Comparison of number of citations to full original articles versus brief reports. Scientometrics, 2013, 94, 203-206.	3.0	7
354	Investigational antimicrobial drugs for bloodstream infections. Current Opinion in Investigational Drugs, 2008, 9, 871-8.	2.3	7
355	Non-physicians may reach correct diagnoses by using Google: a pilot study. Swiss Medical Weekly, 2008, 138, 741-5.	1.6	7
356	Potential Consequences of the Pneumococcal Conjugate Vaccine. New England Journal of Medicine, 2006, 355, 95-96.	27.0	6
357	Infections After Endovascular Coil Embolization. Journal of Endovascular Therapy, 2007, 14, 805-806.	1.5	6
358	Implications of findings of bibliometric analyses in parasitology. Trends in Parasitology, 2007, 23, 12-13.	3.3	6
359	e-meducation.org: an open access medical education web portal. BMC Medical Education, 2008, 8, 6.	2.4	6
360	Respiratory tract infections in a military recruit setting: A prospective cohort study. Journal of Infection and Public Health, 2008, 1, 101-104.	4.1	6

#	Article	IF	Citations
361	Sex differences in the incidence and severity of respiratory tract infections. Respiratory Medicine, 2008, 102, 627.	2.9	6
362	Editorial Commentary:Fosfomycin: The Current Status of the Drug. Clinical Infectious Diseases, 2015, 61, 1144-1146.	5.8	6
363	Medical training in Greece: A crisis in progress. Postgraduate Medicine, 2015, 127, 591-599.	2.0	6
364	Urinary tract infections in patients undergoing radical cystectomy and urinary diversion: challenges and considerations in antibiotic prophylaxis. Translational Andrology and Urology, 2019, 8, 286-289.	1.4	6
365	Secular trends of blood isolates in patients from a rural area population hospitalized in a tertiary center in a small city in Greece. BMC Microbiology, 2006, 6, 41.	3.3	5
366	Treatment of extensively drug-resistant Gram-negative infections in critically ill patients: Outcome of a consensus meeting at the 13th Asia-Pacific Congress of Clinical Microbiology and Infection, October 2012. Journal of Global Antimicrobial Resistance, 2013, 1, 117-122.	2.2	5
367	Vaginal mesh infection due to Bacteroides melaninogenicus: A case report of another emerging foreign body related infection. Scandinavian Journal of Infectious Diseases, 2006, 38, 1108-1110.	1.5	4
368	Knee septic arthritis due to Streptococcus pyogenes associated with acute thrombosis of the tibial and peroneal veins: Case report and review of the literature. Scandinavian Journal of Infectious Diseases, 2007, 39, 368-370.	1.5	4
369	Meta-analyses on the Prevention and Treatment of Respiratory Tract Infections. Infectious Disease Clinics of North America, 2009, 23, 331-353.	5.1	4
370	Treatment of acute bacterial exacerbations of chronic bronchitis. Expert Opinion on Pharmacotherapy, 2009, 10, 1173-1182.	1.8	4
371	In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus. Journal of Antibiotics, 2011, 64, 559-562.	2.0	4
372	Antimicrobial activity and clinical effectiveness of sisomicin: an evaluation of the literature (1995–2011). Expert Review of Anti-Infective Therapy, 2013, 11, 421-428.	4.4	4
373	Impact of oseltamivir use on the reduction of complications in patients with influenza: a prospective study. Archives of Virology, 2016, 161, 2511-2518.	2.1	4
374	An analysis of medical visits at a primary health care center in Kinshasa, Democratic Republic of the Congo (DRC). European Journal of Internal Medicine, 2018, 53, e19-e20.	2.2	4
375	Surveillance of Community Outbreaks of Respiratory Tract Infections Based on House-Call Visits in the Metropolitan Area of Athens, Greece. PLoS ONE, 2012, 7, e40310.	2.5	4
376	Guidelines and Consensus Statements Regarding the Conduction and Reporting of Clinical Research Studies. Archives of Internal Medicine, 2007, 167, 877.	3.8	3
377	Free Internal Medicine Case-Based Education Through the World Wide Web: How, Where, and With What?. Mayo Clinic Proceedings, 2007, 82, 203-207.	3.0	3
378	From the Roots of Parasitology: Hippocrates' First Scientific Observations in Helminthology. Journal of Parasitology, 2007, 93, 970-972.	0.7	3

#	Article	IF	CITATIONS
379	World Wide Web resources on prevention and treatment of postoperative infections. American Journal of Surgery, 2008, 196, 307-310.	1.8	3
380	Openâ€Access World Wide Web Resources on Sepsis. Clinical Infectious Diseases, 2008, 47, 588-588.	5.8	3
381	Comparison of adverse events between oral and intravenous formulations of antimicrobial agents: a systematic review of the evidence from randomized trials. Pharmacoepidemiology and Drug Safety, 2009, 18, 873-879.	1.9	3
382	Infections caused by <i>Acinetobacter baumannii</i> susceptible only to polymyxin in a gynecologic oncology unit. International Journal of Gynecology and Obstetrics, 2009, 105, 264-264.	2.3	3
383	Understanding of Statistical Terms Routinely Used in Meta-Analyses: An International Survey among Researchers. PLoS ONE, 2013, 8, e47229.	2.5	3
384	Patient house calls in Attica and Thessaloniki, Greece (2005-2015): a model for out-of-hospital multispecialty emergency medicine. BMC Health Services Research, 2018, 18, 304.	2.2	3
385	Benefits of prolonged infusion of beta-lactam antibiotics in patients with sepsis: personal perspectives. Expert Review of Anti-Infective Therapy, 2020, 18, 957-966.	4.4	3
386	Temporal Trends (1999–2015) in the Impact Factor of Biomedical Journals Published by US and EU Scientific Societies. Rambam Maimonides Medical Journal, 2018, 9, e0012.	1.0	3
387	Peer review in open access scientific journals. Open Medicine, 2007, 1, e49-51.	1.5	3
388	World Wide Web resources of open access, educational dermatology clinical image quizzes and databases. Journal of the American Academy of Dermatology, 2007, 56, e81-e85.	1.2	2
389	World Wide Web resources on zoonotic infections: a subjective overview. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008, 102, 1181-1188.	1.8	2
390	Trends of tuberculin skin test positivity rate among schoolchildren in Attica, Greece. Scandinavian Journal of Infectious Diseases, 2009, 41, 195-200.	1.5	2
391	Preface. Infectious Disease Clinics of North America, 2009, 23, xiii.	5.1	2
392	A World Wide Web Guide to Pediatric Infectious Diseases. Journal of Tropical Pediatrics, 2010, 56, 265-269.	1.5	2
393	Morbidity and Outcomes of Foreign Travelers in Zakynthos Island, Greece: A Retrospective Study. PLoS ONE, 2014, 9, e94416.	2.5	2
394	Early investigational antibiotics for the treatment of acute exacerbations of chronic bronchitis. Expert Opinion on Investigational Drugs, 2017, 26, 313-317.	4.1	2
395	Women Physicians in Byzantium. World Journal of Surgery, 2017, 41, 892-895.	1.6	2
396	In vitrosusceptibility and resistance phenotypes in contemporaryEnterobacterisolates in a university hospital in Crete, Greece. Future Microbiology, 2017, 12, 683-693.	2.0	2

#	Article	IF	CITATIONS
397	Resistance phenotypes and susceptibility of contemporary (i>Serratia i>isolates in the university hospital of Crete, Greece. Infectious Diseases, 2017, 49, 847-853.	2.8	2
398	A Model for Out-of-Hospital Multispecialty Emergency Medicine: Accomplishments and Challenges. Health Services Insights, 2018, 11, 117863291880599.	1.3	2
399	Trends of Mortality due to Septicemia in Greece: An 8-Year Analysis. PLoS ONE, 2013, 8, e67621.	2.5	2
400	In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancy - response to Prentice et al. British Journal of Haematology, 2006, 132, 658-659.	2.5	1
401	Selection for Candida Non-albicans spp. After Fluconazole Use. Anesthesia and Analgesia, 2008, 107, 2091-2092.	2.2	1
402	Linezolid for the treatment of skin and soft-tissue infections. Expert Review of Dermatology, 2008, 3, 539-548.	0.3	1
403	Re: Semirecumbent position to prevent ventilator-associated pneumonia is not evidence based. Journal of Critical Care, 2010, 25, 153-154.	2.2	1
404	Probiotics for the prevention of ventilator-associated pneumonia. Expert Review of Respiratory Medicine, 2010, 4, 567-571.	2.5	1
405	Ten old antibiotics that will never disappear. Intensive Care Medicine, 2015, 41, 1950-1953.	8.2	1
406	Continuous or Extended Intravenous Administration of $\hat{l}^2$ -Lactam Antibiotics. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1077-1078.	5.6	1
407	Continuous intravenous administration of antibiotics – Authors' reply. Lancet Infectious Diseases, The, 2006, 6, 259-260.	9.1	0
408	Aminoglycosides in combination with a $\hat{A}$ -lactam for the treatment of bacterial endocarditis: authors' response. Journal of Antimicrobial Chemotherapy, 2006, 57, 1255-1256.	3.0	0
409	World Wide Web Resources on Obstetrical and Gynecological Infections. Infectious Diseases in Obstetrics and Gynecology, 2007, 2007, 1-3.	1.5	0
410	Thiazolidinedione therapy and restenosis after coronary stent implantation. American Heart Journal, 2007, 154, e43.	2.7	0
411	Matching Criteria in Case-Control Studies in the Field of Antimicrobial Resistance. Microbial Drug Resistance, 2008, 14, 171-182.	2.0	0
412	Open-access Web resources on cardiovascular infections and inflammations. Canadian Journal of Cardiology, 2008, 24, e11-e15.	1.7	0
413	Urethritis and Dysuria. , 0, , 409-414.		0
414	Mechanical Bowel Preparation for Elective Colorectal Surgery: Is It Enough? Reply. Journal of Gastrointestinal Surgery, 2009, 13, 1395.	1.7	0

#	Article	IF	CITATIONS
415	Edict of Postoperative Fever and Atelectasis: Response. Chest, 2012, 141, 275.	0.8	O
416	Reply to Soman et al and Frippiat et al. Clinical Infectious Diseases, 2013, 57, 325-327.	5.8	0
417	Urethritis and dysuria., 0,, 386-391.		0
418	Biomedical research productivity and economic crisis in Greece: a 22-year study. Scientometrics, 2018, 116, 1559-1564.	3.0	0
419	Addressing clinical safety of antimicrobial resistance: personal perspectives. Expert Review of Anti-Infective Therapy, 2019, 17, 865-869.	4.4	0
420	Internet Resources on Antimicrobial Resistance. , 2009, , 1339-1345.		0
421	Ampicillin–Sulbactam. , 2010, , 204-220.		O
422	Control of Multi-Drug Resistant Acinetobacter Infections. , 2012, , 117-125.		0
423	Internet Resources on Antimicrobial Resistance. , 2017, , 1593-1598.		O